« Return to News | CROs/Service Providers

ICON reports quarterly revenue up 5%

Friday, February 17, 2012 01:43 PM

ICON, a global CRO, has reported financial results for the full year and for the fourth quarter ending Dec. 31, 2011.

For the fourth quarter, net revenues grew 5% year on year to $242.6 million and operating income was $6.6 million, representing 3% of revenue, compared to $22 million or 9% for the year-ago quarter. Net income was $4.1 million compared with $22.1 million last year, or $0.07 per share compared to $0.36 in the year-ago quarter.

For the full year 2011, revenue grew 5.1% to $946 million and operating income before non-recurring charges was $39.3 million, representing 4.2% of revenue, compared to $92 million or 10.2% in 2010. On a U.S. GAAP basis, income from operations was $29.4 million, compared with $92 million in the prior year.

Net income before non-recurring charges was $31.5 million, a net margin of 3.3%, compared to $87.1 million and 9.7% of revenue a year ago. EPS before non-recurring charges for 2011 was $0.52 per share, compared with $1.44 in 2010. On a U.S. GAAP basis, net income was $22.8 million, a net margin of 2.4%, compared to $87.1 million and 9.7% of revenue a year ago. EPS on a GAAP basis for 2011 was $0.37 per share compared with $1.44 in 2010.

Share:          
CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks ex-U.S. toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

Copyright © 1995-2012 CenterWatch.